This is a promotional website intended for UK healthcare professionals only.

Apraclonidine 1% w/v Eye Drops, Solution (apraclonidine hydrochloride) Prescribing Information can be found here. Adverse Event Reporting Information can be found at the end of this page.

Keeping intraocular pressure in check

Apraclonidine 1% w/v is indicated to control or prevent post-surgical elevations in intraocular pressure that occur in patients after anterior segment laser surgery. (Clinical trials have been conducted in trabeculoplasty, iridotomy and capsulotomy).1

An elderly person smiling
Photograph of Apraclonidine 1% w/v preservative‑free eye‑drop bottle beside its product box, showing the product label and dosage information.

What is Apraclonidine 1% w/v and how does it work?

Apraclonidine 1% w/v is a potent and relatively selective α2-adrenergic receptor agonist.2 Several studies show that apraclonidine lowers IOP by decreasing aqueous production through its action on α2-adrenoreceptors of the nonpigmented ciliary epithelium.2

Apraclonidine 1% w/v is the only medication licensed for the control or prevention of post-surgical elevations in IOP after anterior segment laser surgery.1,3

Apraclonidine 1% w/v has been used in ophthalmic care for over 3 decades, following its first FDA approval in 1987.4

Clinical trials have documented the efficacy of Apraclonidine 1% w/v in trabeculoplasty, iridotomy and capsulotomy.1

Apraclonidine 1% w/v is available as a preservative-free treatment.5

Could Apraclonidine 1% w/v offer your patients control of IOP spikes following anterior segment laser surgery?

Neodymium-doped yttrium aluminum garnet (Nd:YAG) capsulotomy

Study findings demonstrated that Apraclonidine 1% w/v-treated eyes experienced significantly lower mean change in IOP from baseline to 3 hours post-Nd:YAG capsulotomy compared with placebo-treated eyes.6,7

Learn more

Neodymium-doped yttrium aluminum garnet (Nd:YAG) capsulotomy

Apraclonidine 1% w/v-treated eyes demonstrated significantly lower IOP in the 3-hour period following argon laser trabeculoplasty (ALT) compared with placebo-treated eyes in study participants.8

Learn more

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Essential Pharma on +44 (0)1423 850700 or at MedicalInformation-UK@essentialpharmagroup.com.

ALT, argon laser trabeculoplasty; IOP, Intraocular pressure; FDA, Food and Drug Administration; Nd:YAG, neodymium-doped yttrium aluminium garnet.

References
  1. Apraclonidine 1% Summary of Product Characteristics.
  2. Scuderi G et al. Rev Ophthalmol. 2008;3:149-153.
  3. National Institute for Health and Care Excellence. British National Formulary (BNF) Apraclonidine. Available from https://bnf.nice.org.uk/drugs/apraclonidine/ [Accessed March 2026]
  4. National Center for Biotechnology Information. PubChem Compound Summary for CID 51763, Apraclonidine Hydrochloride. Available from https://pubchem.ncbi.nlm.nih.gov/compound/Apraclonidine-Hydrochloride [Accessed March 2026].
  5. NHS Business Services Authority. Dictionary of Medicines and Devices (dm+d) Browser: Apraclonidine 1% eye drops. Available from: https://dmd-browser.nhsbsa.nhs.uk/vmp/view/4257 [Accessed March 2026].
  6. Silverstone DE et al. Am J Ophthalmol. 1992;113(4):401-405.
  7. Pollack IP et al. Arch Ophthalmol. 1988;106(6):754-757.
  8. Robin AL et al. Arch Ophthalmol. 1987;105(5):646-650.

Your message was successfully sent. We will be in touch soon.

There was a problem trying to send your message. Please try again.